The biggest difference between ocrelizumab and the recently approved ofatumumab is that ofatumumab can be taken at home for relapsing forms of multiple sclerosis (MS), explained Patricia K. Coyle, MD.

As recently as the ‘90s, when patients arrived with all the typical symptoms — memory loss, double vision, fatigue — neurologists often avoided confirming what they most suspected: that the patient ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio March is Multiple Sclerosis Awareness ...

Multiple sclerosis (MS) is one of the most common autoimmune diseases affecting the brain and spinal cord, with 2.9 million people estimated to be living with the disease worldwide. As MS is an ...

Constipation is a common symptom for people with MS. A variety of lifestyle strategies, medications, and supportive treatments can help.

New MS treatments target myelin repair, neuroprotection, and CNS-resident immune cells, offering hope for progressive forms of the disease. Bruton tyrosine kinase inhibitors (BTKis) like tolebrutinib ...

When Shanel Gamboa's legs started to tingle and go numb last fall, she attributed it to working long shifts as a neuroscience nurse with Lehigh Valley Health Network. But one morning in October, ...

Improvements in safety, efficacy, and specificity have raised questions around the benefits and risks of switching treatments for this type of MS, especially from fingolimod to siponimod. There are ...

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed. A new artificial intelligence ...

VIRGINIA BEACH, Va. (WAVY) — Walk MS is two weeks away, and more than 1,500 people in the area are hard at work fundraising and building their teams. Thanks to funds raised at events like Walk MS, a ...

Please provide your email address to receive an email when new articles are posted on . Risk of treatment discontinuation at 2 years was six times higher with moderately effective therapies. Highly ...